Liso-cel as first treatment for primary CNS lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests an investigational cell therapy called liso-cel for people with primary central nervous system lymphoma who cannot have a stem cell transplant and have already responded to initial chemotherapy. The goal is to see if liso-cel can help control the disease better and possibly improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with primary central nervous system lymphoma (PCNSL), which is lymphoma that started in the brain or spinal cord.
- You are not eligible for a stem cell transplant, for example because you are 65 or older or have other health issues.
- You have received 4 to 6 doses of a standard chemotherapy called high-dose methotrexate and your disease has shrunk or disappeared after that treatment.
- You have not had any other experimental treatments for PCNSL.
- You are able to perform daily activities with some help (ECOG score 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests a type of CAR T-cell therapy (called liso-cel) for people with large B-cell lymphoma who still have tiny traces of cancer after their first treatment. The goal is to see if liso-cel can get rid of those remaining cancer cells and prevent the cancer from coming back.
This trial tests a combination of two drugs for people with large B-cell lymphoma that has spread to the brain or spinal cord and has come back or not responded well to earlier treatments. The first drug, Relma-cel, is a type of immunotherapy that helps your immune system attack cancer cells. The second drug, Tislelizumab, helps keep your immune system active against the cancer.
This study tests a new treatment that combines your own immune cells with a targeted drug and a stem cell transplant for a rare type of brain lymphoma. The goal is to see if this approach can help people whose cancer has returned or not fully responded to initial therapy.
This trial tests a combination of high-dose chemotherapy drugs (gemcitabine, busulfan, and thiotepa) followed by a stem cell transplant for people with primary central nervous system lymphoma. It aims to see if this treatment can improve outcomes for patients whose disease has responded to initial therapy.
This trial tests a combination of radiation, immune-boosting drugs, and a targeted antibody for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma (a type of brain lymphoma). The goal is to see if this approach is safe and effective.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.